Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease
Identifieur interne : 001556 ( Main/Corpus ); précédent : 001555; suivant : 001557Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease
Auteurs : Joseph O'Neill ; Norbert Schuff ; William J. Marks Jr. ; Robert Feiwell ; Michael J. Aminoff ; Michael W. WeinerSource :
- Movement Disorders [ 0885-3185 ] ; 2002-09.
English descriptors
- KwdEn :
Abstract
Magnetic resonance imaging (MRI) and 1H magnetic resonance spectroscopy (MRS) of the substantia nigra, basal ganglia, and cerebral cortex were performed on 10 patients with Parkinson's disease (PD) and 13 age‐matched, healthy control subjects. Compared to controls, PD patients had approximately 24% lower creatine in the region of the substantia nigra and smaller volumes of the putamen (11%), globus pallidus (16%), and prefrontal cortex (6%; all P < 0.05). No other significant between‐group differences were found in nine regions examined. Thus, quantitative MRI may show regional neurodegenerative changes outside the substantia nigra in PD but PD‐linked extranigral metabolic abnormalities, if they exist, may be difficult to detect with current 1H MRS methods. In additional, exploratory tests, volumes of the caudate (r = −0.56), putamen (r = −0.66), and globus pallidus (r = −0.60; all P < 0.05) were negatively correlated with the volume of the substantia nigra pars compacta in controls. In PD these correlations did not hold. Instead, pallidal volume in PD was positively correlated with compacta volume (r = 0.64; P < 0.05). This relationship suggests that basal ganglia volumes may be influenced by dopaminergic innervation from the substantia nigra in normal and PD subjects. © 2002 Movement Disorder Society
Url:
DOI: 10.1002/mds.10214
Links to Exploration step
ISTEX:2E21BB8FBBCC3EA4F3D14B9FE80E45EDCAB5D97BLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease</title><author><name sortKey="O Neill, Joseph" sort="O Neill, Joseph" uniqKey="O Neill J" first="Joseph" last="O'Neill">Joseph O'Neill</name><affiliation><mods:affiliation>Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: joneill@mednet.ucla.edu</mods:affiliation></affiliation></author><author><name sortKey="Schuff, Norbert" sort="Schuff, Norbert" uniqKey="Schuff N" first="Norbert" last="Schuff">Norbert Schuff</name><affiliation><mods:affiliation>Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</mods:affiliation></affiliation></author><author><name sortKey="Marks Jr, William J" sort="Marks Jr, William J" uniqKey="Marks Jr W" first="William J." last="Marks Jr.">William J. Marks Jr.</name><affiliation><mods:affiliation>Center for Parkinson's Disease and Movement Disorders, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of California, San Francisco, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Feiwell, Robert" sort="Feiwell, Robert" uniqKey="Feiwell R" first="Robert" last="Feiwell">Robert Feiwell</name><affiliation><mods:affiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</mods:affiliation></affiliation></author><author><name sortKey="Aminoff, Michael J" sort="Aminoff, Michael J" uniqKey="Aminoff M" first="Michael J." last="Aminoff">Michael J. Aminoff</name><affiliation><mods:affiliation>Center for Parkinson's Disease and Movement Disorders, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of California, San Francisco, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Weiner, Michael W" sort="Weiner, Michael W" uniqKey="Weiner M" first="Michael W." last="Weiner">Michael W. Weiner</name><affiliation><mods:affiliation>Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2E21BB8FBBCC3EA4F3D14B9FE80E45EDCAB5D97B</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10214</idno><idno type="url">https://api.istex.fr/document/2E21BB8FBBCC3EA4F3D14B9FE80E45EDCAB5D97B/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001556</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease</title><author><name sortKey="O Neill, Joseph" sort="O Neill, Joseph" uniqKey="O Neill J" first="Joseph" last="O'Neill">Joseph O'Neill</name><affiliation><mods:affiliation>Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: joneill@mednet.ucla.edu</mods:affiliation></affiliation></author><author><name sortKey="Schuff, Norbert" sort="Schuff, Norbert" uniqKey="Schuff N" first="Norbert" last="Schuff">Norbert Schuff</name><affiliation><mods:affiliation>Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</mods:affiliation></affiliation></author><author><name sortKey="Marks Jr, William J" sort="Marks Jr, William J" uniqKey="Marks Jr W" first="William J." last="Marks Jr.">William J. Marks Jr.</name><affiliation><mods:affiliation>Center for Parkinson's Disease and Movement Disorders, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of California, San Francisco, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Feiwell, Robert" sort="Feiwell, Robert" uniqKey="Feiwell R" first="Robert" last="Feiwell">Robert Feiwell</name><affiliation><mods:affiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</mods:affiliation></affiliation></author><author><name sortKey="Aminoff, Michael J" sort="Aminoff, Michael J" uniqKey="Aminoff M" first="Michael J." last="Aminoff">Michael J. Aminoff</name><affiliation><mods:affiliation>Center for Parkinson's Disease and Movement Disorders, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of California, San Francisco, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Weiner, Michael W" sort="Weiner, Michael W" uniqKey="Weiner M" first="Michael W." last="Weiner">Michael W. Weiner</name><affiliation><mods:affiliation>Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-09">2002-09</date><biblScope unit="volume">17</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="917">917</biblScope><biblScope unit="page" to="927">927</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">2E21BB8FBBCC3EA4F3D14B9FE80E45EDCAB5D97B</idno><idno type="DOI">10.1002/mds.10214</idno><idno type="ArticleID">MDS10214</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>basal ganglia</term><term>brain atrophy</term><term>dopamine</term><term>magnetic resonance imaging</term><term>magnetic resonance spectroscopy</term><term>substantia nigra</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Magnetic resonance imaging (MRI) and 1H magnetic resonance spectroscopy (MRS) of the substantia nigra, basal ganglia, and cerebral cortex were performed on 10 patients with Parkinson's disease (PD) and 13 age‐matched, healthy control subjects. Compared to controls, PD patients had approximately 24% lower creatine in the region of the substantia nigra and smaller volumes of the putamen (11%), globus pallidus (16%), and prefrontal cortex (6%; all P < 0.05). No other significant between‐group differences were found in nine regions examined. Thus, quantitative MRI may show regional neurodegenerative changes outside the substantia nigra in PD but PD‐linked extranigral metabolic abnormalities, if they exist, may be difficult to detect with current 1H MRS methods. In additional, exploratory tests, volumes of the caudate (r = −0.56), putamen (r = −0.66), and globus pallidus (r = −0.60; all P < 0.05) were negatively correlated with the volume of the substantia nigra pars compacta in controls. In PD these correlations did not hold. Instead, pallidal volume in PD was positively correlated with compacta volume (r = 0.64; P < 0.05). This relationship suggests that basal ganglia volumes may be influenced by dopaminergic innervation from the substantia nigra in normal and PD subjects. © 2002 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Joseph O'Neill PhD</name><affiliations><json:string>Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</json:string><json:string>Department of Radiology and Neurology, University of California, San Francisco, California USA</json:string><json:string>E-mail: joneill@mednet.ucla.edu</json:string></affiliations></json:item><json:item><name>Norbert Schuff PhD</name><affiliations><json:string>Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</json:string><json:string>Department of Radiology and Neurology, University of California, San Francisco, California USA</json:string></affiliations></json:item><json:item><name>William J. Marks Jr. MD</name><affiliations><json:string>Center for Parkinson's Disease and Movement Disorders, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</json:string><json:string>Department of Neurology, University of California, San Francisco, California, USA</json:string></affiliations></json:item><json:item><name>Robert Feiwell MD</name><affiliations><json:string>Department of Radiology and Neurology, University of California, San Francisco, California USA</json:string></affiliations></json:item><json:item><name>Michael J. Aminoff MD</name><affiliations><json:string>Center for Parkinson's Disease and Movement Disorders, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</json:string><json:string>Department of Neurology, University of California, San Francisco, California, USA</json:string></affiliations></json:item><json:item><name>Michael W. Weiner MD</name><affiliations><json:string>Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</json:string><json:string>Department of Radiology and Neurology, University of California, San Francisco, California USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>magnetic resonance spectroscopy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>magnetic resonance imaging</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>substantia nigra</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>basal ganglia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>brain atrophy</value></json:item></subject><articleId><json:string>MDS10214</json:string></articleId><language><json:string>eng</json:string></language><abstract>Magnetic resonance imaging (MRI) and 1H magnetic resonance spectroscopy (MRS) of the substantia nigra, basal ganglia, and cerebral cortex were performed on 10 patients with Parkinson's disease (PD) and 13 age‐matched, healthy control subjects. Compared to controls, PD patients had approximately 24% lower creatine in the region of the substantia nigra and smaller volumes of the putamen (11%), globus pallidus (16%), and prefrontal cortex (6%; all P > 0.05). No other significant between‐group differences were found in nine regions examined. Thus, quantitative MRI may show regional neurodegenerative changes outside the substantia nigra in PD but PD‐linked extranigral metabolic abnormalities, if they exist, may be difficult to detect with current 1H MRS methods. In additional, exploratory tests, volumes of the caudate (r = −0.56), putamen (r = −0.66), and globus pallidus (r = −0.60; all P > 0.05) were negatively correlated with the volume of the substantia nigra pars compacta in controls. In PD these correlations did not hold. Instead, pallidal volume in PD was positively correlated with compacta volume (r = 0.64; P > 0.05). This relationship suggests that basal ganglia volumes may be influenced by dopaminergic innervation from the substantia nigra in normal and PD subjects. © 2002 Movement Disorder Society</abstract><qualityIndicators><score>7.924</score><pdfVersion>1.4</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>7</keywordCount><abstractCharCount>1323</abstractCharCount><pdfWordCount>6463</pdfWordCount><pdfCharCount>41104</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>202</abstractWordCount></qualityIndicators><title>Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>17</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>11</total><last>927</last><first>917</first></pages><issn><json:string>0885-3185</json:string></issn><issue>5</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2002</publicationDate><copyrightDate>2002</copyrightDate><doi><json:string>10.1002/mds.10214</json:string></doi><id>2E21BB8FBBCC3EA4F3D14B9FE80E45EDCAB5D97B</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/2E21BB8FBBCC3EA4F3D14B9FE80E45EDCAB5D97B/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/2E21BB8FBBCC3EA4F3D14B9FE80E45EDCAB5D97B/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/2E21BB8FBBCC3EA4F3D14B9FE80E45EDCAB5D97B/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><availability><p>WILEY</p></availability><date>2002</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease</title><author><persName><forename type="first">Joseph</forename><surname>O'Neill</surname></persName><roleName type="degree">PhD</roleName><email>joneill@mednet.ucla.edu</email><affiliation>Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</affiliation><affiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</affiliation></author><author><persName><forename type="first">Norbert</forename><surname>Schuff</surname></persName><roleName type="degree">PhD</roleName><affiliation>Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</affiliation><affiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</affiliation></author><author><persName><forename type="first">William J.</forename><surname>Marks Jr.</surname></persName><roleName type="degree">MD</roleName><affiliation>Center for Parkinson's Disease and Movement Disorders, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</affiliation><affiliation>Department of Neurology, University of California, San Francisco, California, USA</affiliation></author><author><persName><forename type="first">Robert</forename><surname>Feiwell</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</affiliation></author><author><persName><forename type="first">Michael J.</forename><surname>Aminoff</surname></persName><roleName type="degree">MD</roleName><affiliation>Center for Parkinson's Disease and Movement Disorders, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</affiliation><affiliation>Department of Neurology, University of California, San Francisco, California, USA</affiliation></author><author><persName><forename type="first">Michael W.</forename><surname>Weiner</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: MR Unit, DVAMC 114M, 4150 Clement Street, San Francisco, CA 9412</p></note><affiliation>Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</affiliation><affiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-09"></date><biblScope unit="volume">17</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="917">917</biblScope><biblScope unit="page" to="927">927</biblScope></imprint></monogr><idno type="istex">2E21BB8FBBCC3EA4F3D14B9FE80E45EDCAB5D97B</idno><idno type="DOI">10.1002/mds.10214</idno><idno type="ArticleID">MDS10214</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2002</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Magnetic resonance imaging (MRI) and 1H magnetic resonance spectroscopy (MRS) of the substantia nigra, basal ganglia, and cerebral cortex were performed on 10 patients with Parkinson's disease (PD) and 13 age‐matched, healthy control subjects. Compared to controls, PD patients had approximately 24% lower creatine in the region of the substantia nigra and smaller volumes of the putamen (11%), globus pallidus (16%), and prefrontal cortex (6%; all P < 0.05). No other significant between‐group differences were found in nine regions examined. Thus, quantitative MRI may show regional neurodegenerative changes outside the substantia nigra in PD but PD‐linked extranigral metabolic abnormalities, if they exist, may be difficult to detect with current 1H MRS methods. In additional, exploratory tests, volumes of the caudate (r = −0.56), putamen (r = −0.66), and globus pallidus (r = −0.60; all P < 0.05) were negatively correlated with the volume of the substantia nigra pars compacta in controls. In PD these correlations did not hold. Instead, pallidal volume in PD was positively correlated with compacta volume (r = 0.64; P < 0.05). This relationship suggests that basal ganglia volumes may be influenced by dopaminergic innervation from the substantia nigra in normal and PD subjects. © 2002 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>magnetic resonance spectroscopy</term></item><item><term>magnetic resonance imaging</term></item><item><term>substantia nigra</term></item><item><term>basal ganglia</term></item><item><term>dopamine</term></item><item><term>brain atrophy</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2001-03-29">Received</change><change when="2002-02-19">Registration</change><change when="2002-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/2E21BB8FBBCC3EA4F3D14B9FE80E45EDCAB5D97B/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="50"><doi origin="wiley" registered="yes">10.1002/mds.v17:5</doi><numberingGroup><numbering type="journalVolume" number="17">17</numbering><numbering type="journalIssue">5</numbering></numberingGroup><coverDate startDate="2002-09">September/October 2002</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="70" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.10214</doi><idGroup><id type="unit" value="MDS10214"></id></idGroup><countGroup><count type="pageTotal" number="11"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Article</title></titleGroup><copyright ownership="thirdParty">Copyright © 2002 Movement Disorders Society</copyright><eventGroup><event type="manuscriptReceived" date="2001-03-29"></event><event type="manuscriptRevised" date="2002-01-02"></event><event type="manuscriptAccepted" date="2002-02-19"></event><event type="publishedOnlineEarlyUnpaginated" date="2002-04-10"></event><event type="firstOnline" date="2002-04-10"></event><event type="publishedOnlineFinalForm" date="2002-09-26"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.5 mode:FullText source:FullText result:FullText" date="2010-04-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">917</numbering><numbering type="pageLast">927</numbering></numberingGroup><correspondenceTo>MR Unit, DVAMC 114M, 4150 Clement Street, San Francisco, CA 9412</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS10214.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="47"></count><count type="wordTotal" number="6218"></count></countGroup><titleGroup><title type="main" xml:lang="en">Quantitative <sup>1</sup>H magnetic resonance spectroscopy and MRI of Parkinson's disease</title><title type="short" xml:lang="en">Proton MR Spectroscopy in Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Joseph</givenNames><familyName>O'Neill</familyName><degrees>PhD</degrees></personName><contactDetails><email>joneill@mednet.ucla.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Norbert</givenNames><familyName>Schuff</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3 #af4"><personName><givenNames>William J.</givenNames><familyName>Marks</familyName><nameSuffix>Jr.</nameSuffix><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Robert</givenNames><familyName>Feiwell</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af3 #af4"><personName><givenNames>Michael J.</givenNames><familyName>Aminoff</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Michael W.</givenNames><familyName>Weiner</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Center for Parkinson's Disease and Movement Disorders, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of California, San Francisco, California, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">magnetic resonance spectroscopy</keyword><keyword xml:id="kwd3">magnetic resonance imaging</keyword><keyword xml:id="kwd4">substantia nigra</keyword><keyword xml:id="kwd5">basal ganglia</keyword><keyword xml:id="kwd6">dopamine</keyword><keyword xml:id="kwd7">brain atrophy</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Magnetic resonance imaging (MRI) and <sup>1</sup>H magnetic resonance spectroscopy (MRS) of the substantia nigra, basal ganglia, and cerebral cortex were performed on 10 patients with Parkinson's disease (PD) and 13 age‐matched, healthy control subjects. Compared to controls, PD patients had approximately 24% lower creatine in the region of the substantia nigra and smaller volumes of the putamen (11%), globus pallidus (16%), and prefrontal cortex (6%; all <i>P</i> < 0.05). No other significant between‐group differences were found in nine regions examined. Thus, quantitative MRI may show regional neurodegenerative changes outside the substantia nigra in PD but PD‐linked extranigral metabolic abnormalities, if they exist, may be difficult to detect with current <sup>1</sup>H MRS methods. In additional, exploratory tests, volumes of the caudate (r = −0.56), putamen (r = −0.66), and globus pallidus (r = −0.60; all <i>P</i> < 0.05) were negatively correlated with the volume of the substantia nigra pars compacta in controls. In PD these correlations did not hold. Instead, pallidal volume in PD was positively correlated with compacta volume (r = 0.64; <i>P</i> < 0.05). This relationship suggests that basal ganglia volumes may be influenced by dopaminergic innervation from the substantia nigra in normal and PD subjects. © 2002 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Proton MR Spectroscopy in Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Quantitative</title></titleInfo><name type="personal"><namePart type="given">Joseph</namePart><namePart type="family">O'Neill</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</affiliation><affiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</affiliation><affiliation>E-mail: joneill@mednet.ucla.edu</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Norbert</namePart><namePart type="family">Schuff</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</affiliation><affiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">William J.</namePart><namePart type="family">Marks Jr.</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Center for Parkinson's Disease and Movement Disorders, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</affiliation><affiliation>Department of Neurology, University of California, San Francisco, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert</namePart><namePart type="family">Feiwell</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael J.</namePart><namePart type="family">Aminoff</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Center for Parkinson's Disease and Movement Disorders, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</affiliation><affiliation>Department of Neurology, University of California, San Francisco, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael W.</namePart><namePart type="family">Weiner</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA</affiliation><affiliation>Department of Radiology and Neurology, University of California, San Francisco, California USA</affiliation><description>Correspondence: MR Unit, DVAMC 114M, 4150 Clement Street, San Francisco, CA 9412</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2002-09</dateIssued><dateCaptured encoding="w3cdtf">2001-03-29</dateCaptured><dateValid encoding="w3cdtf">2002-02-19</dateValid><copyrightDate encoding="w3cdtf">2002</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="tables">2</extent><extent unit="references">47</extent><extent unit="words">6218</extent></physicalDescription><abstract lang="en">Magnetic resonance imaging (MRI) and 1H magnetic resonance spectroscopy (MRS) of the substantia nigra, basal ganglia, and cerebral cortex were performed on 10 patients with Parkinson's disease (PD) and 13 age‐matched, healthy control subjects. Compared to controls, PD patients had approximately 24% lower creatine in the region of the substantia nigra and smaller volumes of the putamen (11%), globus pallidus (16%), and prefrontal cortex (6%; all P < 0.05). No other significant between‐group differences were found in nine regions examined. Thus, quantitative MRI may show regional neurodegenerative changes outside the substantia nigra in PD but PD‐linked extranigral metabolic abnormalities, if they exist, may be difficult to detect with current 1H MRS methods. In additional, exploratory tests, volumes of the caudate (r = −0.56), putamen (r = −0.66), and globus pallidus (r = −0.60; all P < 0.05) were negatively correlated with the volume of the substantia nigra pars compacta in controls. In PD these correlations did not hold. Instead, pallidal volume in PD was positively correlated with compacta volume (r = 0.64; P < 0.05). This relationship suggests that basal ganglia volumes may be influenced by dopaminergic innervation from the substantia nigra in normal and PD subjects. © 2002 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>magnetic resonance spectroscopy</topic><topic>magnetic resonance imaging</topic><topic>substantia nigra</topic><topic>basal ganglia</topic><topic>dopamine</topic><topic>brain atrophy</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>917</start><end>927</end><total>11</total></extent></part></relatedItem><identifier type="istex">2E21BB8FBBCC3EA4F3D14B9FE80E45EDCAB5D97B</identifier><identifier type="DOI">10.1002/mds.10214</identifier><identifier type="ArticleID">MDS10214</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2002 Movement Disorders Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001556 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001556 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:2E21BB8FBBCC3EA4F3D14B9FE80E45EDCAB5D97B
|texte= Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |